Extracorporeal Immunoadsorption for the Treatment of Coagulation Inhibitors

ABSTRACT

Extracorporeal immunoadsorption is a widely used technique for the removal of pathogenic antibodies in a variety of immunologic disorders. This procedure has been used in patients with high-titer inhibitors against coagulation factors for the temporary removal of antibodies before initiating replacement therapy to achieve hemostasis and stop acute bleeding or to cover a surgical procedure. Inhibitor removal by immunoadsorption has also been included at the onset of immune tolerance protocols in both acquired and congenital hemophilia. This article summarizes the current knowledge on the use of this technique in patients with inhibitors against coagulation factors. Overall, the published literature documents that extracorporeal immunoadsorption is a safe and useful technique for the elimination of coagulation inhibitors. However, further randomized clinical trials are needed to better assess the cost-effectiveness of such procedures.

KEYWORDS

Immunoadsorption - bleeding - inhibitors - hemophilia

REFERENCES

• 1 Briet E, Rosendaal F R, Kreuz W et al.. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products.  Thromb Haemost. 1994;  72 162-164
• 2 Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review.  Am J Hematol. 2005;  80 55-63
• 3 Fulcher C A, de Graaf Mahoney S, Zimmerman T S. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting.  Blood. 1987;  69 1475-1480
• 4 Saenko E L, Ananyeva N M, Kouiavskaia D V et al.. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action.  Haemophilia. 2002;  8 1-11
• 5 Berntorp E, Shapiro A, Astermark J et al.. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.  Haemophilia. 2006;  12(Suppl 6) 1-7
• 6 von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety.  Haemophilia. 2005;  11(Suppl 1) 18-23
• 7 DiMichele D M, Hoots W K, Pipe S W, Rivard G E, Santagostino E. International workshop on immune tolerance induction: consensus recommendations.  Haemophilia. 2007;  13(Suppl 1) 1-22
• 8 Freedman J, Garvey M B. Immunoadsorption of factor VIII inhibitors.  Curr Opin Hematol. 2004;  11 327-333
• 9 Francesconi M, Korninger C, Thaler E, Niessner H, Höcker P, Lechner K. Plasmapheresis: its value in the management of patients with antibodies to factor VIII.  Haemostasis. 1982;  11 79-86
• 10 Knöbl P, Derfler K. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.  Vox Sang. 1999;  77(Suppl1) 57-64
• 11 Astermark J. Treatment of the bleeding inhibitor patient.  Semin Thromb Hemost. 2003;  29 77-86
• 12 Nilsson I M, Freiburghaus C. Apheresis.  Adv Exp Med Biol. 1995;  386 175-184
• 13 Nilsson I M, Jonsson S, Sundqvist S B, Ahlberg A, Bergentz S E. A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies.  Blood. 1981;  58 38-44
• 14 Morrison F S, Huestis D W. Toxicity of the staphylococcal protein A immunoadsorption column.  J Clin Apher. 1992;  7 171-172
• 15 Kabisch A, Kroll H, Wedi B, Kiefel V, Pralle H, Mueller-Eckhardt C. Severe adverse effects of protein A immunoadsorption.  Lancet. 1994;  343 116
• 16 Berntorp E. Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.  Haemophilia. 2006;  12(Suppl 6) 62-65
• 17 Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B M, Nilsson I M. Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.  Haemophilia. 1998;  4 16-20
• 18 Gjörstrup P, Berntorp E, Larsson L, Nilsson I M. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption.  Vox Sang. 1991;  61 244-250
• 19 Nilsson I M, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.  N Engl J Med. 1988;  318 947-950
• 20 Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson I M. Tolerance induction using the Malmö treatment model 1982–1995.  Haemophilia. 1999;  5 32-39
• 21 Rivard G E, St Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution.  Haemophilia. 2003;  9 711-716
• 22 Jansen M, Schmaldienst S, Banyai S et al.. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).  Br J Haematol. 2001;  112 91-97
• 23 Knöbl P, Derfler K, Korninger L et al.. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb).  Thromb Haemost. 1995;  74 1035-1038
• 24 Tribl B, Knöbl P, Derfler K et al.. Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.  Ann Hematol. 1995;  71 199-203
• 25 Taleghani M B, Grossmann R. Treatment of patients with factor VIII autoantibodies by staphylococcal protein A-based immunoadsorption and immunosuppression.  Br J Haematol. 2001;  114 956-958
• 26 Freedman J, Rand M L, Russell O et al.. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII.  Transfusion. 2003;  43 1508-1513
• 27 Zeitler H, Ulrich-Merzenich G, Hess L et al.. Treatment of acquired hemophilia by the Bonn-Malmo protocol: documentation of an in vivo immunomodulating concept.  Blood. 2005;  105 2287-2293
• 28 Brzoska M, Krause M, Geiger H, Betz C. Immunoadsorption with single-use columns for the management of bleeding in acquired hemophilia A: a series of nine cases.  J Clin Apher. 2007;  22 233-240